468 related articles for article (PubMed ID: 28803431)
1. SB2: An Infliximab Biosimilar.
Lamb YN; Scott LJ; Deeks ED
BioDrugs; 2017 Oct; 31(5):461-464. PubMed ID: 28803431
[TBL] [Abstract][Full Text] [Related]
2. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.
Smolen JS; Choe JY; Prodanovic N; Niebrzydowski J; Staykov I; Dokoupilova E; Baranauskaite A; Yatsyshyn R; Mekic M; Porawska W; Ciferska H; Jedrychowicz-Rosiak K; Zielinska A; Lee Y; Rho YH
Ann Rheum Dis; 2018 Feb; 77(2):234-240. PubMed ID: 29042358
[TBL] [Abstract][Full Text] [Related]
3. Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.
Smolen JS; Choe JY; Prodanovic N; Niebrzydowski J; Staykov I; Dokoupilova E; Baranauskaite A; Yatsyshyn R; Mekic M; Porawska W; Ciferska H; Jedrychowicz-Rosiak K; Zielinska A; Choi J; Rho YH
Rheumatology (Oxford); 2017 Oct; 56(10):1771-1779. PubMed ID: 28957563
[TBL] [Abstract][Full Text] [Related]
4. PF-06438179/GP1111: An Infliximab Biosimilar.
Al-Salama ZT
BioDrugs; 2018 Dec; 32(6):639-642. PubMed ID: 30284704
[TBL] [Abstract][Full Text] [Related]
5. Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea.
Kim DW; Lee Y; Kim G; Kim SH; Cho DH; Choi J; Kwon YH; Park Y; Choi W; Park DI
Adv Ther; 2023 Mar; 40(3):1047-1061. PubMed ID: 36624354
[TBL] [Abstract][Full Text] [Related]
6. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.
Choe JY; Prodanovic N; Niebrzydowski J; Staykov I; Dokoupilova E; Baranauskaite A; Yatsyshyn R; Mekic M; Porawska W; Ciferska H; Jedrychowicz-Rosiak K; Zielinska A; Choi J; Rho YH; Smolen JS
Ann Rheum Dis; 2017 Jan; 76(1):58-64. PubMed ID: 26318384
[TBL] [Abstract][Full Text] [Related]
7. GP2013: A Rituximab Biosimilar.
Blair HA
BioDrugs; 2017 Oct; 31(5):465-468. PubMed ID: 28921160
[TBL] [Abstract][Full Text] [Related]
8. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
Blair HA; Deeks ED
BioDrugs; 2016 Oct; 30(5):469-480. PubMed ID: 27650650
[TBL] [Abstract][Full Text] [Related]
9. A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects.
Shin D; Kim Y; Kim YS; Körnicke T; Fuhr R
BioDrugs; 2015 Dec; 29(6):381-8. PubMed ID: 26577771
[TBL] [Abstract][Full Text] [Related]
10. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.
Feagan BG; Lam G; Ma C; Lichtenstein GR
Aliment Pharmacol Ther; 2019 Jan; 49(1):31-40. PubMed ID: 30411382
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence.
Macaluso FS; Cummings JF; Atreya R; Choi J; Orlando A
Expert Opin Biol Ther; 2022 Feb; 22(2):203-223. PubMed ID: 34314284
[TBL] [Abstract][Full Text] [Related]
12. GP2015: An Etanercept Biosimilar.
Deeks ED
BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Clinical Outcomes After Switching from Remicade
Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F
Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429
[TBL] [Abstract][Full Text] [Related]
14. SB5: An Adalimumab Biosimilar.
Frampton JE
BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
[TBL] [Abstract][Full Text] [Related]
15. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
[TBL] [Abstract][Full Text] [Related]
16. Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health.
Braun J; Kudrin A
Biologicals; 2016 Jul; 44(4):257-266. PubMed ID: 27117857
[TBL] [Abstract][Full Text] [Related]
17. A review of CT-P13: an infliximab biosimilar.
McKeage K
BioDrugs; 2014 Jun; 28(3):313-21. PubMed ID: 24723086
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.
McConachie S; Wilhelm SM; Kale-Pradhan PB
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):391-400. PubMed ID: 28095262
[TBL] [Abstract][Full Text] [Related]
20. A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.
Bellinvia S; Ashraf M; Polosa R; Edwards C
Immunotherapy; 2017 Nov; 9(14):1133-1142. PubMed ID: 29067885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]